Karyotypic abnormalities in myelofibrosis following polycythemia vera.

Cancer Genet Cytogenet

Laboratoire de Génétique Médicale, Hôpital Jeanne de Flandre, Barre Nord CHRU, Lille Cedex, France.

Published: January 2003

Polycythemia vera (PV) is a chronic myeloproliferative disease characterized by an increase of total red cell volume; in 10% to 15% of cases, bone marrow fibrosis complicates the course of the disease after several years, resulting in a hematologic picture mimicking myelofibrosis with myelocytic metaplasia (MMM). This condition is known as post polycythemic myelofibrosis (PPMF). Among 30 patients with PPMF followed in Northern France, 27 (90%) expressed one or two abnormal clones in myelocytic cell cultures. Of these, 19 (70%) had partial or complete trisomy 1q. This common anomaly either resulted from unbalanced translocations with acrocentric chromosomes, that is, 13, 14, and 15, or other chromosomes, that is, 1, 6, 7, 9, 16, 19, and Y, or from partial or total duplication of long arm of chromosome 1. A single patient had an isochromosome 1q leading to tetrasomy 1q. In all cases, a common trisomic region spanning 1q21 to 1q32 has been identified. Given that most patients had previously received chemotherapy or radio-phosphorus to control the polycythemic phase of their disease, this study illustrates the increased frequency of cytogenetic abnormalities after such treatments: 90% versus 50% in de novo MMM. Moreover, karyotype can be used to distinguish PPMF-where trisomy 1q is the main anomaly-from primary MMM where trisomy 1q is rare and deletions 13q or 20q are far more common. Whether trisomy 1q is or is not a secondary event remains a matter of debate, as well as the role of cytotoxic treatments.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(02)00678-7DOI Listing

Publication Analysis

Top Keywords

polycythemia vera
8
karyotypic abnormalities
4
abnormalities myelofibrosis
4
myelofibrosis polycythemia
4
vera polycythemia
4
vera chronic
4
chronic myeloproliferative
4
myeloproliferative disease
4
disease characterized
4
characterized increase
4

Similar Publications

Introduction: Polycythemia is a rare condition that can be either primary or secondary. We report a case of an adolescent with progressive hydronephrosis-induced polycythemia and low erythropoietin levels, along with a thorough literature review.

Report Of A Case: A 17-year-old girl with epilepsy had progressively elevated hemoglobin levels and low erythropoietin levels.

View Article and Find Full Text PDF

Acute gastric variceal bleeding is a rare but serious complication of portal hypertension. Initial therapy for bleeding gastric varices focuses on acute hemostasis. In this regard, endoscopic cyanoacrylate injection (ECI) is the first-line approach.

View Article and Find Full Text PDF

Tris(2-chloroethyl) Phosphate Leads to Unbalanced Circulating Erythrocyte in Mice by Activating both Medullary and Extramedullary Erythropoiesis.

Environ Sci Technol

January 2025

Department of Occupational and Environmental Health, School of Public Health, Qingdao University, Qingdao 266071, China.

Tris(2-chloroethyl) phosphate (TCEP), a prevalent organophosphorus flame retardant, has been identified in various environmental matrices and human blood samples, provoking alarm regarding its hematological toxicity, a subject that has not been thoroughly investigated. Red blood cells (RBCs), or erythrocytes, are the predominant cell type in peripheral blood and are crucial for the maintenance of physiological health. This investigation employed oral gavage to examine the effects of TCEP exposure on erythrocyte counts in mice and to clarify the underlying mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the link between elevated vitamin B12 levels and myeloproliferative neoplasms (MPNs), which include types of blood cancers like CML, PV, MF, and ET, suggesting that higher B12 could indicate disease presence and activity.
  • Data from 467 MPN patients showed that 20% had elevated B12 levels, particularly in those with CML, with significant reductions in B12 levels observed after one year of treatment.
  • While increased B12 levels appear related to MPN activity, their effectiveness as a consistent diagnostic marker needs more research to establish reliable sensitivity, specificity, and cutoff values.
View Article and Find Full Text PDF

Background The Janus kinase 2 (JAK2) V617F mutations are related to increased thrombotic risk in patients with myeloproliferative disorders (MPDs). However, little is known about whether inherited thrombophilia represents an additive risk factor in mutated subjects. We addressed the association between combined mutations of JAK2 and factor V Leiden (FVL) and thrombotic complications in Saudi Arabian patients with MPDs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!